EXPO

Phase 4

Conditions: Mild to moderate essential hypertension

Registration Number: JPRN-jRCT1080221127

Lead Sponsor: DAIICHISANKYO Co.,Ltd.

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Sex: All

Target Recruitment: 300

Inclusion Criteria

90<=SeDBP<110mmHg, SeSBP<180mmHg

Exclusion Criteria

None

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

Pulmonary Artery Remodelling With Bosenta

Phase 4

Actelion Phrmaceuticals Australia

Updated 1/13/2020

A Prospective, open-label, non-comparative study to assess the Safety, Tolerability and Efficacy of Voriconazole for the Primary and salvage treatment of Invasive Candidiasis, candidemia and esophageal candiidiasis in pediatric subjects.

Pfizer Inc.

Updated 1/6/2015

A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPHAGEAL CANDIDIASIS IN PEDIATRIC SUBJECTS

Pfizer Inc., 235 East 42nd Street, New York, NY 10017

Updated 7/15/2013

A Prospective, open-label, non-comparative study to assess the Safety,Tolerability and Efficacy of Voriconazole for the Primary and salvagetreatment of Invasive Candidiasis, candidemia and esophageal candiidiasisin pediatric subjects.

Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA

Updated 5/15/2012

A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPHAGEAL CANDIDIASIS IN PEDIATRIC SUBJECTS

Phase 1

Pfizer Inc., 235 East 42nd Street, New York, NY 10017

Updated 4/3/2017

A Prospective, open-label, non-comparative study to assess the Safety, Tolerability and Efficacy of Voriconazole for the Primary and salvage treatment of Invasive Candidiasis, candidemia and esophageal candiidiasis in pediatric subjects.

Pfizer Inc., 235 East 42nd Street, New York, NY 10017

Updated 5/15/2012

A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPHAGEAL CANDIDIASIS IN PEDIATRIC SUBJECTS

Phase 1

Pfizer Inc., 235 East 42nd Street, New York, NY 10017

Updated 12/21/2021

A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPHAGEAL CANDIDIASIS IN PEDIATRIC SUBJECTS

Phase 1

Pfizer Inc., 235 East 42nd Street, New York, NY 10017

Updated 1/17/2022

A comparative Clinical study on the effect of Arjuna-RasonÄ?di yoga & Navaka guggulu On Medodushti

Phase 2

ational Institute Of Ayurveda deemed to be universityjaipur

Updated 2/21/2022

An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months

GlaxoSmithKline Research & Development Ltd

Updated 3/19/2012

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Home Terms & Conditions Privacy Policy